Core Viewpoint - The report outlines the independent financial advisor's assessment of Beijing Innotech Biotechnology Co., Ltd.'s 2025 restricted stock incentive plan, confirming its compliance with relevant laws and regulations, and its potential positive impact on the company's long-term development and shareholder interests [1][2][27]. Group 1: Incentive Plan Overview - The 2025 restricted stock incentive plan is designed to motivate directors, senior management, core technical personnel, and other key employees deemed necessary by the board [4][5]. - The total number of restricted stocks to be granted is 2,112,740 shares, accounting for approximately 1.55% of the company's total share capital at the time of the plan's announcement [8][9]. - The plan includes a reserve portion of 414,500 shares, which represents 19.62% of the total grant [7][8]. Group 2: Grant and Vesting Conditions - The vesting period for the restricted stocks is set for a maximum of 60 months, with specific vesting arrangements based on performance metrics [9][10]. - The initial grant will vest in three phases: 20% after 12 months, 40% after 24 months, and 40% after 36 months [11][12]. - The vesting conditions include achieving specific performance targets related to revenue growth and product registration certificates [19][20]. Group 3: Compliance and Feasibility - The independent financial advisor confirms that the incentive plan complies with the relevant regulations and does not harm the interests of the company or its shareholders [27][28]. - The advisor also notes that the plan's operational procedures are feasible and align with legal requirements [24][25]. - The funding for the incentive plan will come from the participants' own resources, with the company not providing any financial assistance [25][26]. Group 4: Performance Assessment - The performance assessment for the incentive plan includes both company-level and individual-level evaluations, ensuring alignment between employee performance and company goals [30][32]. - The company-level performance indicators focus on revenue growth and the number of product registration certificates obtained, which are critical for the company's market competitiveness [31][32]. - The individual performance assessment will categorize results into four tiers, determining the actual number of shares vested based on performance outcomes [21][22]. Group 5: Long-term Impact - The implementation of the incentive plan is expected to positively influence the company's sustainable operational capacity and shareholder equity, as it aligns the interests of management with those of shareholders [29][30]. - The plan aims to enhance the company's competitive edge and motivate employees, contributing to long-term growth and stability [31][32].

Core Viewpoint - The announcement details the achievement of the first vesting conditions for the reserved grant of the 2024 restricted stock incentive plan, allowing for the vesting of 545,000 shares at an adjusted grant price of 10.03 yuan per share [1][19]. Summary by Sections Stock Incentive Plan Overview - The 2024 restricted stock incentive plan was approved at the first extraordinary general meeting of shareholders in 2024, targeting senior management and core employees, excluding independent directors and supervisors [1]. - The reserved grant includes 4 core employees as incentive recipients [1]. Vesting Arrangement - The first vesting period allows for 50% of the granted shares to vest after 12 months from the grant date, with the remaining 50% vesting after 24 months [2]. - The reserved grant's first vesting period follows the same structure, with 50% vesting after 12 months and the remaining 50% after 24 months [2]. Performance Conditions - The performance assessment for the first vesting period requires a revenue growth rate of no less than 36% in 2024 compared to 2022 [4][13]. - The second vesting period requires a revenue growth rate of no less than 67% in 2025 compared to 2022 [4][13]. Approval Process - The plan underwent necessary approvals, including the review by the board and supervisory committee, confirming that the vesting conditions have been met [6][14]. - The supervisory committee provided verification opinions on the incentive plan and its implementation [16]. Impact on Financials - The vesting of 545,000 shares will increase the total share capital, potentially affecting earnings per share and net asset return rates, but is not expected to have a significant impact on the company's financial status or operational results [17].

证券代码：000716 证券简称：黑芝麻 公告编号：2025-043 南方黑芝麻集团股份有限公司 关于 2023 年限制性股票激励计划 第一个解除限售期解除限售条件成就的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、 本次激励计划简述及已履行的审议程序 于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会 办理公司 2023 年限制性股票激励计划有关事宜的议案》，公司独立董事就本次激励 计划相关事项发表了独立意见，同意公司实施本次激励计划，律师出具了相应的法 律意见书。 于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于核查公司<2023 年限制性 股票激励计划授予激励对象名单>的议案》，监事会已经就本次激励计划相关事项发 表了核查意见，同意公司实施本次激励计划。 授予激励对象的姓名及职务予以公示。公示期内，公司监事会未收到任何员工对本 次激励对象名单提出 ...

Core Viewpoint - The document outlines the rules and regulations governing the Compensation and Assessment Committee of Beijing Innotech Biotechnology Co., Ltd., focusing on the establishment of a robust assessment and incentive mechanism for directors and senior management, in compliance with relevant laws and regulations [1][2]. Group 1: General Provisions - The purpose of the rules is to enhance the assessment and incentive mechanisms for the company's directors and senior management, improving corporate governance structures [1]. - The Compensation and Assessment Committee is a specialized committee under the board of directors, responsible for formulating assessment standards and compensation policies for directors and senior management [1][2]. Group 2: Composition of the Committee - The committee consists of three directors, with independent directors making up the majority [2]. - The committee members are nominated by the chairman, a majority of independent directors, or more than one-third of all directors, and elected by the board [2]. Group 3: Responsibilities and Authority - The committee is tasked with developing assessment standards, reviewing compensation policies, and making recommendations on various matters, including compensation for directors and senior management [4]. - The board has the authority to reject any compensation plans that may harm shareholder interests [4]. Group 4: Evaluation Procedures - The committee requires the company to provide relevant materials for performance evaluation, including financial indicators and management responsibilities [12]. - The evaluation process involves self-assessment by directors and senior management, followed by performance evaluations conducted by the committee [13]. Group 5: Committee Meetings - The committee meets as needed, with meetings called by the chairman or upon request from committee members [14]. - A quorum for meetings requires the presence of at least two-thirds of the committee members, and decisions are made by a majority vote [15][16]. Group 6: Documentation and Confidentiality - Meeting minutes must be recorded, including the opinions of independent directors, and must be kept for at least ten years [10]. - All committee members are bound by confidentiality regarding the matters discussed in meetings [10].

Core Viewpoint - The announcement details the second vesting period of the 2022 restricted stock incentive plan for Shenzhen Oat Technology Co., Ltd, confirming that the vesting conditions have been met for a total of 170,400 shares to 33 eligible participants [1][9][15]. Group 1: Incentive Plan Overview - The total number of restricted shares granted is 4 million, with 3.2 million shares (80%) for the initial grant and 800,000 shares (20%) reserved for future grants [1]. - The purchase price for the shares is set at 8.53 yuan per share [1]. - The incentive plan includes three vesting periods, with specific percentages of shares vesting at each period: 30% after 18 months, 30% after 30 months, and 40% after 42 months for the initial grant [1][3]. Group 2: Performance Assessment Criteria - The performance assessment for the incentive plan will occur annually from 2023 to 2025, with specific revenue growth targets: 20% for 2023, 30% for 2024, and 40% for 2025, based on the average revenue from 2020 to 2022 [2][3]. - If the performance targets are not met, all shares planned for vesting in that year will be canceled [3]. Group 3: Vesting Conditions and Compliance - The second vesting period for the reserved shares has been confirmed, with 33 eligible participants meeting the necessary conditions [9][10]. - The vesting conditions include a minimum tenure of 12 months for participants and compliance with company performance targets [10][12]. - The board has verified that the vesting conditions for the reserved shares have been met, allowing for the vesting of 170,400 shares [12][15]. Group 4: Legal and Regulatory Compliance - The company has received necessary approvals and authorizations for the adjustments and vesting of the restricted shares, ensuring compliance with relevant laws and regulations [15][16]. - The legal opinion confirms that the adjustments and vesting conditions align with the company's articles of association and applicable laws [15][16].

Core Points - The company, Hainan Jinpan Intelligent Technology Co., Ltd., has proposed a 2025 Restricted Stock Incentive Plan to attract and retain talent while aligning the interests of shareholders, the company, and employees [1][7][8] - The plan involves granting 5 million restricted stocks, accounting for approximately 1.09% of the company's total share capital, with 4 million stocks for initial grants and 1 million reserved for future grants [3][16] - The grant price for the restricted stocks is set at 45.89 yuan per share, which is determined based on various pricing methods [4][22] Incentive Plan Details - The incentive plan will be executed over a maximum period of 60 months, with stocks vesting in stages based on performance criteria [5][18] - The plan targets 399 individuals, including senior management, core technical personnel, and key business staff, excluding directors and major shareholders [5][11] - The plan includes performance assessment criteria based on company revenue and net profit targets for the years 2025 to 2027 [24][25] Stock Grant and Vesting Conditions - The restricted stocks will not confer shareholder rights until they are vested, and they cannot be transferred or used as collateral before vesting [2][20] - The vesting conditions require the company to meet specific performance targets, and individual performance assessments will also influence the vesting of stocks [26][28] - The plan stipulates that if any performance conditions are not met, the granted but unvested stocks will be forfeited [24][26] Management and Approval Process - The plan must be approved by the company's shareholders and will be managed by the board of directors, with oversight from the remuneration and assessment committee [10][11][9] - The company commits not to provide any financial assistance to the incentive recipients for acquiring the restricted stocks [6][10] Previous Incentive Plans - The company is currently implementing a 2021 Restricted Stock Incentive Plan, which is independent of the proposed 2025 plan [8][9]

法律意见书 关于深圳市燕麦科技股份有限公司 第二个归属期归属条件成就、部分限制性股票作废以及 第一个归属期归属条件成就相关事项的 法律意见书 中国广东深圳市福田区益田路 6001 号太平金融大厦 11、12 楼 邮编：518038 电话（Tel）：（0755）88265288 传真（Fax）：（0755）88265537 法律意见书 法律意见书 | 释义 | | | | --- | --- | --- | | 在本法律意见书内，除非文义另有所指，下列简称和词语具有以下含义： | | | | 深圳市燕麦科技股份有限公司 | 公司 指 | | | 符合 | | 2022 年激励计划、2023 年激励计划授予条件的激励对象，在 | | 指 | 限制性股票 | 满足相应归属条件后分次获得并登记的公司股票，为第二类限制性 | | 股票 | | | | 根据 | | 2022 年激励计划、2023 年激励计划的相关规定获得限制性股 | | 指 | 激励对象 | | | 票的人员 | | | | 公司 | | 2022 年激励计划以及 2023 年激励计划授予价格（含预留授予） | | 指 | 本次调整 | | | 的调整 ...

薪酬与考核委员会实施细则 第一章 总则 第一条 为进一步建立健全广东安达智能装备股份有限公司（以下简称"公 司"）薪酬与考核管理制度,完善公司治理结构,根据《中华人民共和国公司法》 《上 市公司治理准则》《上海证券交易所科创板股票上市规则》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》《广东安达智能装备股份有限 公司章程》（以下简称"《公司章程》"）及其他有关规定，公司特设立董事会薪 酬与考核委员会，并制定本细则。 广东安达智能装备股份有限公司 第二条 薪酬与考核委员会是董事会下设的专门工作机构，主要负责制定董 事、高级管理人员的考核标准并进行考核，制定、审查董事、高级管理人员的薪 酬政策与方案，并向董事会提出意见和建议。 第三条 本细则所称董事是指包括独立董事在内的由股东会选举产生的全 体董事；高级管理人员是指董事会聘任的总经理、副总经理、董事会秘书、财务 总监及《公司章程》规定的其他高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成，独立董事占多数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者全体 董事的三分之一以上提名，并由董事会以全体 ...

Core Viewpoint - The announcement confirms that the conditions for the second exercise period of the stock option plan have been met, allowing eligible participants to exercise their options [1][20][25]. Summary by Sections Stock Option Plan Overview - The stock option plan involves the issuance of 151,530 stock options at an exercise price of 12.409 CNY per share [1][22]. - The eligible participants include 11 individuals, primarily middle management and core technical/business personnel [22][24]. Exercise Conditions - The second exercise period is defined as the period from 24 months after the initial grant date until 36 months after, with a 30% exercise ratio [17][23]. - The performance targets for the exercise periods are based on revenue growth rates, with specific targets set for 2023, 2024, and 2025 [5][19]. Performance Assessment - The performance assessment will be conducted annually, with specific revenue growth targets set at 20% for 2023, 30% for 2024, and 60% for 2025, based on the 2022 revenue of 560.3494 million CNY [5][19]. - The company will evaluate individual performance based on a set of criteria, determining the actual number of options that can be exercised [6][19]. Approval Process - The plan has undergone various approvals, including board meetings and shareholder meetings, ensuring compliance with legal and regulatory requirements [8][9][10]. - The company has received independent opinions from financial advisors and legal counsel confirming the validity of the exercise conditions [26][27]. Financial Impact - The exercise of options will increase the total share capital by 151,530 shares, with minimal impact on earnings per share and overall financial results [24][25]. - The funds raised from the exercise will be used to supplement the company's working capital [24]. Conclusion - The company confirms that all conditions for the second exercise period have been met, and the eligible participants can proceed with exercising their options [20][25].

Core Viewpoint - The Shanghai Medicilon Inc. has received approval from its Board of Directors' Compensation and Assessment Committee for its 2025 Restricted Stock Incentive Plan, indicating compliance with relevant laws and regulations [1][4]. Summary by Sections Compliance with Regulations - The company confirms that there are no prohibitive circumstances under the relevant laws and regulations for implementing the stock incentive plan, including the Company Law and Securities Law [2][3]. - The plan's initial grant recipients meet the qualifications set forth in the Company Law, Securities Law, and other relevant regulations [3][4]. Incentive Plan Details - The initial grant recipients are core employees of the company and its subsidiaries, excluding independent directors and supervisors, ensuring compliance with the incentive object conditions [3][4]. - The plan's formulation, review process, and content adhere to the legal requirements, and the granting arrangements do not infringe on the interests of the company and its shareholders [4]. Governance and Objectives - The implementation of the incentive plan is expected to enhance the company's governance structure, attract and retain talent, and align the interests of shareholders, the company, and the core team [4].